 |
|
A simple, noninvasive test measures survival time in adult pulmonary hypertension
November 01, 2006Researchers have developed a simple, noninvasive way to measure right ventricular function in the heart to predict survival of adults who suffer from pulmonary hypertension.
The research appears in the first issue for November 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
Paul M. Hassoun, M.D., of the Divisions of Cardiology, Pulmonary and Critical Care Medicine at Johns Hopkins Hospital in Baltimore, and 11 associates studied 63 consecutive patients with pulmonary hypertension. After right heart catheterization, these patients underwent a transthoracic echocardiogram to assess right ventricular performance in the heart.
Study participants were mostly female, white and had an average age of 55. Seventy-five percent (47 patients) met the World Health Organization's group 1 diagnostic classification of pulmonary hypertension.
Pulmonary hypertension involves progressive narrowing of the blood vessels in the lungs, which can lead to death. In 2000, 163,000 patients discharged from U.S. hospitals had been diagnosed with primary pulmonary hypertension. Although the problem is difficult to detect in a routine medical exam, doctors see more rapid clinical deterioration in patients who have the greatest degree of right ventricular dysfunction.
To assess the problem, researchers performed a test called tricuspid annular plane systolic excursion (TAPSE), which measures echocardiographic abnormalities in the tricuspid valve. Located between the heart's right atrium and right ventricle, the valve prevents the backflow of blood as it is pumped from the right atrium to the right ventricle.
"We found that a TAPSE of less than 1.8 cm was associated with a greater ventricular systolic dysfunction, as well as right heart remodeling," said Dr. Hassoun. "In addition, survival estimates at one and two years for those with pulmonary arterial hypertension were 94 percent and 88 percent, respectively, for individuals with a TAPSE of 1.8 cm or greater. If the TAPSE was less, the survival rates were 60 percent at one year and 50 percent at two years."
The researchers said that patients with a TAPSE of less than 1.8 cm, showing more advanced right ventricular dysfunction, had a dramatically reduced survival rate over the average follow-up time of 19 months. Patients with a TAPSE of less than 1.5 cm had an especially poor outcome.
"Our results suggest that TAPSE is a robust measure of right ventricular function and a powerful predictor of patient survival in pulmonary hypertension," said Dr. Hassoun.
The investigators noted that they believed the TAPSE test should be incorporated into the echocardiographic assessment of all patients were pulmonary artery hypertension.
American Thoracic Society
Study participants were mostly female, white and had an average age of 55. Seventy-five percent (47 patients) met the World Health Organization's group 1 diagnostic classification of pulmonary hypertension.
Pulmonary hypertension involves progressive narrowing of the blood vessels in the lungs, which can lead to death. In 2000, 163,000 patients discharged from U.S. hospitals had been diagnosed with primary pulmonary hypertension. Although the problem is difficult to detect in a routine medical exam, doctors see more rapid clinical deterioration in patients who have the greatest degree of right ventricular dysfunction.
To assess the problem, researchers performed a test called tricuspid annular plane systolic excursion (TAPSE), which measures echocardiographic abnormalities in the tricuspid valve. Located between the heart's right atrium and right ventricle, the valve prevents the backflow of blood as it is pumped from the right atrium to the right ventricle.
"We found that a TAPSE of less than 1.8 cm was associated with a greater ventricular systolic dysfunction, as well as right heart remodeling," said Dr. Hassoun. "In addition, survival estimates at one and two years for those with pulmonary arterial hypertension were 94 percent and 88 percent, respectively, for individuals with a TAPSE of 1.8 cm or greater. If the TAPSE was less, the survival rates were 60 percent at one year and 50 percent at two years."
The researchers said that patients with a TAPSE of less than 1.8 cm, showing more advanced right ventricular dysfunction, had a dramatically reduced survival rate over the average follow-up time of 19 months. Patients with a TAPSE of less than 1.5 cm had an especially poor outcome.
"Our results suggest that TAPSE is a robust measure of right ventricular function and a powerful predictor of patient survival in pulmonary hypertension," said Dr. Hassoun.
The investigators noted that they believed the TAPSE test should be incorporated into the echocardiographic assessment of all patients were pulmonary artery hypertension.
American Thoracic Society
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Allergic Reaction Attractiveness Climate Warming Mass Extinction Water Molecules Gold Nanoparticles Dark Matter Radiofrequency Ablation Rhinovirus Mastectomy Allergic Reactions Pulmonary Hypertension World Trade Center Genome Sequencing Immune Response Cholesterol Levels Juvenile Idiopathic Arthritis Obstructive Sleep Apnea Hydrothermal Vents Flavanols Behavioral Problems Emotions Blood Sugar HPV vaccine Brain Tumors
See More: Science News Tags
Pulmonary Hypertension Current Events and Pulmonary Hypertension News RSSSevere obesity increases risks of health problems during surgery
Healthcare providers must carefully consider the unique risk factors related to severe obesity in patients undergoing all types of surgery, according to an American Heart Association scientific advisory published in Circulation: Journal of the American Heart Association.
Gene therapy technique thwarts cancer by cutting off tumor blood supply
University of Florida researchers have come up with a new gene therapy method to disrupt cancer growth by using a synthetic protein to induce blood clotting that cuts off a tumor's blood and nutrient supply.
Sleep Apnea Increases Heart Disease Risk
Obstructive sleep apnea, or periodic interruptions in breathing throughout the night, thickens sufferers' blood vessels. Moreover, it increases the risk of several forms of heart and vascular disease.
Chemical can reproduce complications for some patients
Medical science took a giant leap forward with the development of techniques that, at least temporarily, perform the function of vital organs.
Pulmonary hypertension in children may result from reduced activity of gene regulator
Too little activity by gene regulators called PPARs appears to be a major player in the irreversible lung damage that can occur in children with heart defects, researchers say.
Researchers may have found why women have an edge on salt-sensitive hypertension
Researchers may have found why women have an edge in keeping a healthier balance between the amount of salt they eat and excrete - at least before reaching menopause.
Research examines variations of rare lung disease
Lymphangioleiomyomatosis, or LAM, is a rare but serious lung disease that may cause severe respiratory symptoms in patients. The often-fatal disease has no cure.
Serum sodium predicts mortality 10 times higher in PAH patients
Patients with pulmonary arterial hypertension (PAH)-chronically high blood pressure in the blood vessels of the lungs-whose serum sodium levels are low (called hyponatremia, or HN) have a very poor chance of survival and a high rate of right-heart failure (RHF), according to new research from the University of Pennsylvania.
New approach to protect the hearts of patients with muscular dystrophy
A team of researchers has recently shown that the administration of sildenafil protects the heart in mice with Duchenne muscular dystrophy.
UCSF marks a milestone with 500th transplant in heart and lung program
UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.
More Pulmonary Hypertension Current Events and Pulmonary Hypertension News Articles
 |
Pulmonary Hypertension (Contemporary Cardiology) by Nicholas S. Hill (Author), Nicholas S. Hill (Editor), Harrison W. Farber (Editor) This timely volume addresses the areas of pathophysiology and therapy of pulmonary hypertension, which have seen exciting developments over the past decade. The discoveries of endothelin overexpression as well as prostacyclin and nitric oxide deficiency in association with pulmonary hypertension have led to important therapeutic insights. In addition, the identification of genes associated with pulmonary hypertension has just begun to open the door to new pathophysiologic insights. The new therapies have led to significant improvements in patient function, quality of life and survival. This book will be of interest not only to cardiologists, pulmonary specialists and rheumatologists, but also many nurses and pharmacotherapists are becoming increasingly involved in the therapy of... |
 |
Identifying Pulmonary Hypertension Pulmonary Hypertension is a rare, complex disease of the heart and lungs. It most commonly strikes women in childbearing years, though it can affect all ages, races and both sexes. This program will identify what pulmonary hypertension is, and how it is treated. Though there is not yet a cure for this illness, treatments have emerged over the last decade, giving patients hope for a longer, healthier life. Meet patients who are living with pulmonary hypertension and demonstrate how to improve your quality of life. We'll also outline the genesis of the Pulmonary Hypertension Association, and illustrate the power people can have to organize, draw attention to a cause and work to improve the lives of patients and families coping with serious illnesses. This program is part of the award... |
 |
Pulmonary Arterial Hypertension: Pocketbook by Taylor & Francis This pocketbook is a concise summary of latest evidence-based information on the diagnosis, assessment and treatment of pulmonary arterial hypertension. Dr Simon Stewart is one of the world's leading nursing experts on cardiac disease, especially heart failure. Highly illustrated, clearly and succinctly written, the book provides an introduction to pulmonary arterial hypertension. It contains clear guidelines for the effective treatment of pulmonary arterial hypertension and emphasizes the need for screening of high-risk patients and outlines the range and effectiveness of treatment options once PAH has been diagnosed. |
 |
Hypertril for Pulmonary Hypertension - Normalize blood pressure levels - Bio-Enhanced Extraction Technology by HP-Hypertril A number of studies have demonstrated that increased free radical activity plays an important role in all cases of high blood pressure, because increased free radicals cause cellular damage and inactivate nitric oxide. Nitric oxide, an important molecular regulator of blood pressure, helps control blood pressure by dilating blood vessels. Antioxidants, powerful free radical scavengers, may help restore activities of nitric oxide and help to control blood pressure. This is the main theoretical basis of HypertrilTM. In addition to antioxidant activities, Hypertril also provides essential nutrients to support blood pressure control and improve circulation. In a study performed at the Institut de Cardiologie de Montreal, Canada, Hypertril demonstrated a significant reduction in MAP (Mean... |
 |
Pulmonary Arterial Hypertension: Diagnosis and Evidence-Based Treatment by Robyn Barst (Editor) First book dedicated to this disease, previously thought to be incurable, but with the advent of new drugs, now amenable to management and a much improved prognosis for patients From the PAH Association, the leading experts in field Incorporates the latest AACP management guidelines Includes evidence-based treatment algorithms based on the recently updated ACCP Guidelines for Medical Treatment Aimed at specialists in pulmonology and cardiovascular disease, this volume provides the clinician with the most up to date information on the effective management of PAH |
 |
Pulmonary Hypertension Awareness Ribbon Mouse Pad by MyHeritageWear.com The Pulmonary Hypertension Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Pulmonary Hypertension Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Pulmonary Hypertension Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Pulmonary Hypertension (Contemporary Cardiology) by Humana Press This timely volume addresses the areas of pathophysiology and therapy of pulmonary hypertension, which have seen exciting developments over the past decade. The discoveries of endothelin overexpression as well as prostacyclin and nitric oxide deficiency in association with pulmonary hypertension have led to important therapeutic insights. In addition, the identification of genes associated with pulmonary hypertension has just begun to open the door to new pathophysiologic insights. The new therapies have led to significant improvements in patient function, quality of life and survival. This book will be of interest not only to cardiologists, pulmonary specialists and rheumatologists, but also many nurses and pharmacotherapists are becoming increasingly involved in the therapy of... |
 |
Balanceuticals Blood Circulator Dietary Supplement Capsules, 500 mg, 60-Count Bottle by Balanceuticals Dietary Supplement. 100% Natural. Made under Supervision by China Academy of Traditional Chinese Medicine. Made of medicinal rhubarb, prepared rehmannia root, common peony root, peach seed, bitter apricot seed, licorice root, scute, dun fly, gadfly, leech, June beetle, this time-honored formula is used in Chinese medicine to promote micro-circulation, increase blood flow to heart muscles, open and clear arteries, inhibit intestinal adhesion, soothe the liver, remove stasis and maintain healthy blood circulation and regular menses. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. |
 |
The Official Patient's Sourcebook on Primary Pulmonary Hypertension by James N. Parker (Editor), Philip M. Parker (Editor) This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to primary pulmonary hypertension (also familial primary pulmonary hypertension; idiopathic pulmonary hypertension; primary obliterative pulmonary vascular disease; primary pulmonary vascular disease; pulmonary hypertension), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from... |
 |
Interactions of Blood and the Pulmonary Circulations by Wiley-Blackwell Univ. of Minnesota, Minneapolis. Focuses on the interaction of blood with the pulmonary vessels. Explains the interaction with the endothelium of sickle cells, platelets, leukocytes, and the clotting cases in the genesis of lung injury and hypertension. For researchers and clinicians. |
| © 2009 BrightSurf.com |